DAVID ROGER GREELEY, MD, FAAN

Born: Seattle, WA 9/19/1962

DRG23, PLLC — Medical Education, Research and Consulting

26 E 5th Avenue Spokane, WA 99202
ph (509) 747-5615 fax (509) 747-5133

drg@drg23.com www.drg23.com

Board-Certified Clinical Neurologist
Fellow, American Academy of Neurology

Medical Director
- Kingfisher Cooperative, LLC
- Kingfisher TMS
- Kindred Healthcare, North Spokane, WA
- Regenerative Medicine Institute, Medical Lake, WA

Qualified NFL Baseline Assessment Program (BAP) Provider
Qualified NFL Monetary Award Fund (MAF) Provider

Principal Investigator, Phase II-IV Pharmaceutical Research Studies
- HM Research
- Spokane Neuro Research

University of Washington School of Medicine

Associate Professor, Department of Neurology
Clinical Faculty, MBB Block WWAMI Spokane
Admissions Committee

EDUCATION

Spring 1993	Honorary Assistant House Physician The National Hospital for Neurology and Neurosurgery Queen Square, London, England
1992 - 1993	Chief Resident in Neurology University of Wisconsin Hospital & Clinics
1990 - 1992	Resident in Neurology University of Wisconsin Hospital & Clinics
1989 - 1990	Internship in Medicine University of Wisconsin Hospital & Clinics
1985 - 1989	Doctor of Medicine University of Washington, Seattle, Washington
1980 - 1985	Bachelor of Arts, Music Theory and History University of Washington, Seattle, Washington
1976 - 1980	Shorewood High School, Seattle, Washington
1974 - 1976	Albert Einstein Junior High School, Seattle, Washington
1969 - 1974	Sunset Elementary School, Seattle, Washington
1968	Edmonds Unitarian Church Sunday School, Rev. Robert Fulghum *All I Really Need to Know I Learned in Kindergarten*

BOARDS & LICENSURE

1994	American Board of Psychiatry and Neurology Re-certified 2004 Re-certified 2015
1993	Washington State Department of Health License #MD00030536
1990	National Board of Medical Examiners

PAST POSITIONS AND HONORS

- Northwest Neurological, PLLC (1999-2018)
- President — Spokane Society for Neurologic Sciences (2009-2010)
- Adjunct Clinical Associate Professor in Pharmacy (2000-2014)
  College of Pharmacy — Washington State University, Pullman, Washington
- Education Committee —Worldwide Education and Awareness for Movement Disorders (2005-2013)
- Consultant — Deep Brain Stimulation Program (2005-2007)
  Seattle Neuroscience Institute at Swedish Medical Center, Seattle, Washington
- Board Member — Washington State Neurological Society (2005-2006)
- Medical Director — Deep Brain Stimulation Program (2004-2005)
  Northwest Hospital, Seattle, Washington
- Clinical Instructor in Psychiatry and Behavioral Sciences (2000-2006)
  University of Washington School of Medicine, Seattle, Washington
- Medical Director of Neurology and Neurophysiology Programs (1999-2002)
  Deaconess Medical Center, Spokane, Washington
- Board Member — Rockwood Clinic, PS
  Spokane, Washington (1997-1998)
- President — Spokane Society for Neurologic Sciences (1997-1998)
- Board of Trustees and Director of Research — Rockwood Clinic Foundation for Medical Research
  Spokane, Washington (1997-1999)
- Director of Recruiting — Rockwood Clinic, PS
  Spokane, Washington (1996-1998)
- Clinical Instructor, Department of Medicine (1995-2001)
  University of Washington School of Medicine, Seattle, Washington
- Neurologist — Rockwood Clinic, PS
  Spokane, Washington (1993-1999)

CLINICAL RESEARCH — PRINCIPAL INVESTIGATOR

1. Glaxo Wellcome: "The Impact of Oral Sumatriptan (Imitrex®) on the Productivity, Quality of Life and Health Care Use in Nursing Personnel with Migraines" (1993–1995)

2. Glaxo Wellcome: "A Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of a Second Sumatriptan (Imitrex®) Tablet in the Acute Treatment of Migraine Subjects who do not have Relief Following an Initial Dose of Sumatriptan (Imitrex®)" (1996)

3. Boehringer Ingelheim/Cambridge Neuroscience: "A Phase II/III Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of Intravenous Aptiganel Versus Placebo in Patients with an Acute Ischemic Stroke" (1996–1997) **JAMA. 2001; 286:2673-2682** http://jama.highwire.org/cgi/content/abstract/286/21/2673

4. Allergan: "A Multicenter, Double-blind, Placebo-controlled, Parallel, Graduated-dose Clinical Trial of Botulinum Toxin, Type A (Botox®) for the Treatment of Chronic Low Back Muscle Spasm" (1996)

5. Janssen: "A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Alniditan Given Subcutaneous in Acute Treatment of Migraine" (1997)

6. Janssen: "An Open Evaluation of the Long-Term Efficacy, Safety and Tolerability of Alniditan Subcutaneous in the Acute Treatment of Migraine Attacks" (1997)

7. Novartis: "An Open-label Study to Evaluate the Safety and Efficacy of Rivastigmine (Exelon®) in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting" (1997–1999)

8. Glaxo Wellcome: "A Randomized, Double-blind, Double-dummy, Active/Placebo-controlled, Parallel Group Evaluation of Oral Naratriptan (Amerge®) Compared to Oral Sumatriptan (Imitrex®) on Migraine Related Quality of Life" (1997–1999)

9. Glaxo Wellcome: "A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Naratriptan (Amerge®) for the Treatment of Migraine in Subjects who do not Respond to Sumatriptan (Imitrex®)" (1997–1999)

10. McNeil: "A Single-dose, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Acetaminophen, Aspirin and Caffeine (Excedrin Migraine®) for the Treatment of Migraine Head Pain" (1998) **Headache 2001; 41:665-679**
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1526-4610.2006.00351_4.x

11. Pharmacia & Upjohn: "Oral Almotriptan (Axert®) vs. Oral Sumatriptan (Imitrex®) in a Double-blind, Randomized, Parallel Group Study of Cost-effectiveness and Quality of Life in Migraine" (1999–2000)

12. SmithKline Beecham: "Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion" (1999-2001)

13. Boston Life Sciences: "An Evaluation of the Safety and Efficacy of Altropane for the Detection of Parkinsonian Syndrome in Patients with Movement Disorders" (1999–2000)

CLINICAL RESEARCH — PRINCIPAL INVESTIGATOR — continued

14. Janssen: "An Open-label Study to Demonstrate Equivalence of Twice Daily Dosing of Galantamine (Razadyne®) Compared to Once Daily Dosing of Vitamin E in Regard to Compliance and to Determine Caregiver and Physician Satisfaction with Galantamine (Razadyne®) in the Treatment of Patients with Alzheimer's Disease Using a Satisfaction Questionnaire" (2000–2001)

15. Daiichi: "A Double-blind, Placebo-controlled, Dose Ranging Study of Nefiracetam in Patients with Post-Stroke Depression" (2000–2001)

16. Novartis: "A Multicenter, Double-blind, Placebo-controlled Study of the Tolerability and Effect of Entacapone in Parkinson's Subjects with End of Dose Wearing Off Symptoms Occurring No Earlier than Four Hours After Their Most Recent Sinemet® Dose" (2000–2001)

17. Independent Research: "Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson's Disease" — FDA Investigational Device Exemption (2000–2001)

18. Pharmacia: "A Multi-center, Randomized, Double-blind, Parallel Group, Multiple Dose Comparison Study of Valdecoxib 20mg, Valdecoxib 40mg, Sumatriptan 50mg and Placebo in Patients with Moderate or Severe Acute Migraine Headache" (2001–2002)

19. Novartis: "Rivastigmine (Exelon®) Capsules in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting" (2001)

20. Pharmacia: "To Assess Efficacy and Tolerability Outcomes Associated with the use of Almotriptan (Axert®) in an Office-based Setting for Adult Patients with Migraine (With or Without Aura) Having 1-6 Migraines Per Month" (2001)

21. Sepracor: "A Randomized, Double-blind, Placebo-controlled and Open-label Twelve Month Study of the Safety of Escopiclone (Lunesta®) in Adult Subjects with Insomnia" (2001–2002)

22. Bristol-Myers-Squibb: "A Double-blind, Placebo-controlled, Randomized, Parallel-group Safety, Efficacy and Dose Response Trial of Two Different Dose Levels of Clopidogrel (Plavix®) in Patients with Signs and Symptoms of Acute Ischemic Stroke" (2001–2002)

23. Bristol-Myers Squibb: "A Double-blind, Placebo-controlled, Safety, Efficacy and Dose Response Trial of Three Intravenous Doses of Clopidogrel (Plavix®) in Patients with Acute Stroke" (2001–2002)

24. Pharmacia: "Multicenter, Randomized, Double-blind, Parallel Group, Multiple Dose Comparison Study of Almotriptan (Axert®) vs. Placebo in Patients with Moderate or Severe Acute Migraine Headache" (2002)

25. Pharmacia: "A Phase III, Double-blind, Placebo-controlled, Randomized Study Comparing the Efficacy, Safety and Tolerability of Sumanirole vs. Placebo or Ropinirole (ReQuip®) in Patients with Early Parkinson's Disease" (2002–2003)

26. Pharmacia: "A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Fixed Dose Response Study Comparing the Efficacy and Safety of Pramipexole (Mirapex®) versus Placebo in Patients with Early Parkinson's Disease" (2003–2004)

CLINICAL RESEARCH — PRINCIPAL INVESTIGATOR — continued

27. Pharmacia: "A Long-Term, Open-label, Flexible-dose Study of the Efficacy and Safety of Sumanirole in Patients with Idiopathic Restless Legs Syndrome" (2003–2004)

28. Bertek: "A Registry Study to Evaluate the Implications of Motor Fluctuations in Parkinson's Disease on Chronic Therapy" (2003–2004)

29. Pharmacia: "A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Fixed Dose Response Study Comparing the Efficacy and Safety of Sumanirole versus Placebo in Patients with Early Parkinson's Disease" Protocol #DA2APD-0075-031 (2003–2005)

30. Kyowa: "A 12-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center, Fixed Dose-Response Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Doses of Istradefylline as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy" (2004–2005)

31. Kyowa: "A Long-Term, Multi-center, Open-label Safety Study with Oral 20 or 40 mg Doses of Istradefylline as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy" (2004–2005)

32. Merck KGaA: "A Double-blind, Placebo-controlled, Multi-center, Multi-national Phase III Study to Evaluate the Safety and Efficacy of Sarizotan 1 mg bid in Patients with Parkinson's Disease Suffering from Treatment-associated Dyskinesia" Protocol #018 (2004–2005)

33. Kyowa: "A Phase II, Double- Blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Efficacy and Safety of 40 mg/day Istradefylline as Monotherapy in Subjects with Parkinson's Disease" Protocol #051 (2005–2007)

34. GlaxoSmithKline: "A 12-Week, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy of Ropinirole CR (ReQuip®) in Patients with Restless Legs Syndrome" Protocol # 205 (2005–2006)

35. Novartis: "A Study to Assess the Sensitivity and Specificity of the Wearing-Off Questionnaire-9" (2005–2006) **Parkinsonism Relat Disord 2007 Sep 25**

36. Novartis: "A Prospective, Multi-center, Randomized, Open-label Study with Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Entacapone on Motor Function and Quality of Life in Patients with Parkinson's Disease with End-of-dose Wearing Off" (2005)

37. Endo: "A Randomized, Double-blind Study Comparing the Safety and Efficacy of the Lidocaine (Lidoderm®) Patch 5% with Placebo in Patients with Pain From Carpal Tunnel Syndrome" (2006)

38. Kyowa: "An Open-label, Multi-center, Study of the Continued Safety of Istradefylline in Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline" (2005–2006)

39. GlaxoSmithKline: "A 52-Week, Open-label Study to Assess the Long-term Safety of Ropinirole CR (ReQuip®) in Patients with Restless Legs Syndrome" (2005–2006)

CLINICAL RESEARCH — PRINCIPAL INVESTIGATOR — continued

40. Pfizer: "A 16-week, Randomized, Double-blind, Placebo and Pregabalin (Lyrica®) Controlled, Multi-center Trial of [S,S]-Reboxetine in Patients with Post-Herpetic Neuralgia" (2006-2007)

41. Pfizer: "An open-label extension trial assessing the safety and tolerability of [S,S]-Reboxetine in patients with Postherpetic Neuralgia" (2006–2008)

42. Merz: "A Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial with a Double-blind Parallel-group Extension Period to Investigate the Efficacy and Safety of Different Doses of Botulinum Toxin, Type A in the Treatment of Cervical Dystonia" (2006-2009)

43. Acadia: "A Multi-center, Placebo-controlled, Double-blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease" (2007–2009)

44. Ortho-McNeil Janssen: "A Randomized, Double-blind, Placebo-controlled, Crossover, Proof of Concept Study to Evaluate the Efficacy and Safety of Carisbamate in the Treatment of Essential Tremor" (2007-2009)

45. Schwarz-Pharma: "A Double-blind, Placebo-controlled Study that is Investigating the Dose Response of the Rotigotine Transdermal Patch" (2007–2009)

46. Boehringer Ingelheim: "A Randomized, Double-blind, Active (pramipexole 0.5 mg tid) and Placebo-controlled, Efficacy Study of Pramipexole given 0.5 mg and 0.75 mg bid over a 12-week Treatment Phase in Early Parkinson's Disease Patients" (2007-2008)

47. Allergan, Inc.: Cervical Dystonia – Patient Registry for Observation of Botox Efficacy (CD-PROBE) (2009)

48. Schwarz Biosciences: Named Patient Program With Rotigotine Transdermal System (SP 953) (2011-2012)

49. Merz: "A Phase IV, Prospective, Observational Trial Evaluating Xeomin (Incobotulinumtoxin A) for Cervical Dystonia or Blepharospasm in the United States" Protocol Number MRZ 60201-4066-5 (2011-2012)

50. Biogen Idec Inc: Stratify 2 - "JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri" Protocol Number 101JC402 (2011)

51. Teva Pharmaceuticals: "A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Doses of Dopamine Agonists in the Treatment of Early Parkinson's Disease. Protocol Number TVP-1012/PM103 (2012-2013). ANDANTE: Add-ON to Dopamine Agonists in early stage patients Needing enhanced Treatment Efficacy (2011-2012)

52. Axovant Sciences, Ltd: "A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects with Mild to Moderate Alzheimer's Disease" (2015 - 2016)

CLINICAL RESEARCH — PRINCIPAL INVESTIGATOR — continued

53. Eli Lilly and Company: "A Phase 3, Randomized, Double-blind, Placebo-controlled Study of LY2951742 in Patients with Episodic Migraine" (2015 - 2017)

54. Eli Lilly and Company: "A Phase 3, Randomized, Double-blind, Placebo-controlled Study of LY2951742 in Patients with Chronic Migraine" (2015 - 2017)

55. Acadia Pharmaceuticals, Inc.: "A Double-blind, Placebo-controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease" (2016 - 2017)

56. Dr. Reddy's Laboratories: "A Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura (2016 - 2017)

57. Neurim Pharmaceuticals: "A Phase 2, Randomized, Double-blind, Parallel-Group, Placebo-controlled, Dose-Ranging Study of Piromelatine in Patients with Mild Dementia due to Alzheimer's Disease (2016 - 2017)

58. Biogen: "A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease" (2016 - present)

59. Axovant Sciences, Ltd: "A Long-term, Open-label Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Alzheimer's Disease" (2016 - 2017)

60. Allergan, Inc.: "A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study To Evaluate The Efficacy, Safety, And Tolerability of Multiple Dosing Regimens of Oral AGN-241689 In Episodic Migraine Prevention (2016 - present)

61. Alzheimer's Association: "Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study" (2016 - 2017)

62. Alder BioPharmaceuticals, Inc: A Parallel Group, Double-blind, Randomized, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine (2017)

63. Eli Lilly and Company: "Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease in the US (GERAS-US)" (2017 - present)

64. Janssen: "A Phase 2b/3 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study Investigating the Efficacy and Safety of JNJ-5481911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer's Dementia (EARLY). (2017 - present)

CLINICAL RESEARCH — SUB INVESTIGATOR

1. Bristol-Myers Squibb: "Clopidogrel (Plavix®) vs. Aspirin in Patients with RIND or TIA" (1996)

2. Parke-Davis: "A Four Month, Double-blind, Dose-Controlled, Parallel Group, Multicenter Study to Determine the Efficacy and Safety of Gabapentin (Neurontin®) in Newly Diagnosed Patients with Partial Epilepsy" (1997–1999)

3. Interneuron: "The Effects of Citicoline Clinical Outcome and the Evolution of Lesion Volume in Human Stroke" (1998–1999)

4. Novartis: "A Multi-center, Double-blind, Placebo-controlled, Randomized, Parallel-group Trial of rufinamide as Adjunctive Therapy in Patients with Inadequately-controlled Primary Generalized Tonic-Clonic Seizures" (1998–1999)

5. Novartis: "A Multi-center, Randomized, Double-blind Placebo-controlled, Parallel, Add-on Trial of oxcarbazepine Tablets in Children with Inadequately-controlled Partial-onset Seizures: Long-term Extension" Phase III. (1998–1999)

6. Novartis: "A Double-blind, Placebo-controlled, Randomized, Parallel Group Trial of Oxcarbazepine (Trileptal®) as Adjunctive Therapy in Patients with Inadequately-controlled Primary Generalized Tonic-Clonic Seizures" (1999–2000)

7. Lundbeck NA, Ltd: "RESTORE: A Clinical Study of Patients with Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy" (2015-2016)

CONFERENCE POSTERS

1. Deep Brain Stimulation in the STN for Intractable Multiple Sclerosis Tremor (P122). Movement Disorder Society 10th International Congress, Kyoto, Japan 2006 PO Shortt, **DR Greeley**, P Nora

2. Identifying the Presence of Dyskinesia in Patients with Parkinson's Disease from Accelerometer Data. American Society of Mechanical Engineering (ASME) 2013 Summer Bioengineering Conference. Darnell ND, Krishnan NC, Carlson JD, **Greeley DR**, Mark J, Schmitter-Edgecombe M, Lin D

3. Clinical Features of Dystonia and Botulinum Toxins XCiDaBLE: An Observational, Prospective Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States – Interim Results from the First 145 Subjects with Cervical Dystonia (P07.192) American Academy of Neurology 66th Annual Meeting, Philadelphia, PA (2014) Hubert Fernandez, Fernando Pagan, Fabio Danisi, **David Greeley**, Joseph Jankovic, Amit Verma, Kapil Sethi and Eric Pappert.

4. Clinical Features of Dystonia and Botulinum Toxins XCiDaBLE: An Observational, Prospective Trial Evaluating Xeomin (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States - Final Results from the Cervical Dystonia Cohort. (P3.009) American Academy of Neurology 67th Annual Meeting (April 2015). Hubert Fernandez, Fernando Pagan, Fabio Danisi, **David Greeley**, Joseph Jankovic, Amit Verma, Kapil Sethi and Eric Pappert

5. A Retrospective Analysis of 73 Patients Switched From onabotulinumtoxinA (Botox®) to incobotulinumtoxinA (Xeomin®) (Posters518) 19th International Congress of Parkinson's Disease and Movement Disorders, San Diego, CA (2015) **David Greeley, MD, FAAN**

6. "Are You Smarter than a Ten Year Old?" (P3-280) Alzheimer's Association International Conference (AAIC). London, England, July 18, 2017 Victoria Karschney, **David Greeley, MD**

CONTRIBUTOR TO RESEARCH PUBLICATIONS

1. The North American Survey of Placement and Adjustment Strategies for Deep Brain Stimulation. Stereotact Funct Neurosurg 2005;83:142-147. Ondo WG, et al. for the DBS Study Group.

2. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia Journal of the Neurological Sciences: 2011, JNS-11837 Comella C, et al. on behalf of the U.S. XEOMIN Cervical Dystonia Study Group.

3. Sustained Efficacy and Safety of Repeated incobotulinumtoxinA (Xeomin) Injections in Blepharospasm. J Neural Transm (Vienna). 2013 Sep;120(9):1345-53 Truong DD, et al. for the Xeomin US Blepharospasm Study Group.

4. A Randomized Study of Rotigotine Dose Response on 'off' time in Advanced Parkinson's Disease. J Parkinsons Dis. 2014;4(3):361-73. Nicholas AP, et al. for the SP921 Study Investigators.

PUBLICATIONS

1. Neuroimmunophilin Ligands: A Novel Treatment for Parkinson's Disease. *Consult Pharm* 2001; 16(8): 767-770. Harrell J, Setter SM, **Greeley DR**.

2. Current Therapeutic Approaches to the Treatment of Parkinson's Disease. *Washington Pharmacy* 2003: 24-29, Winter Demos R, Setter SM, **Greeley DR**, Johnson K.

3. Potential Advances in the Treatment of Parkinson's Disease. *Advances in Pharmacy.* 3(3); 226-238, Summer 2005 Setter SM, Iltz JL, **Greeley DR**.

4. Review of HIV-Associated Dementia (HIV-D). *Advances in Pharmacy.* 3(3); 214-225, Summer 2005 Thams J, Setter SM, Terriff C, **Greeley DR**.

5. Dementia with Lewy Bodies. U.S. Pharmacist, April 2006. Sonnett T, Setter SM, **Greeley DR**.

6. Normal Pressure Hydrocephalus. U.S. Pharmacist 2007; 1:56-61. http://www.uspharmacist.com/content/t/neurology/c/10438/ Neumiller JJ, Neumiller JJ, Gates BJ, Setter SM, **Greeley DR**.

7. The Sensitivity and Specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 2007 Sep 25 Stacy MA, Murphy JM, **Greeley DR**, Stewart RM, Murck H, Meng X.

8. Characterizing Multiple Memory Deficits and their Relation to Everyday Functioning in Individuals with Mild Cognitive Impairment. Neuropsychology 2009, Vol. 23, No. 2, 168-177. Schmitter-Edgecombe M, Woo E, **Greeley D**.

9. Istradefylline as Monotherapy for Parkinson Disease: Results of the 6002-US-051 Trial. Parkinsonism Relat Disord 2010;16:16 –20. Fernandez HH, **Greeley DR**, Zweig RM, Wojcieszek J, Mori A, Sussman NM.

10. Gamma Knife Radiosurgery for Essential Tremor: A Case Report and Review of the Literature. World J Surg Oncol. 2010 Mar 22;8:20. doi: 10.1186/1477-7819-8-20. Review. Elaimy AL, Demakas JJ, Arthurs BJ, Cooke BS, Fairbanks RK, Lamoreaux WT, Mackay AR, **Greeley DR**, Lee CM.

11. Gamma Knife Radiosurgery for Movement Disorders: A Concise Review of the Literature. World J Surg Oncol. 2010 Jul 21;8:61. doi: 10.1186/1477-7819-8-61. Review. Elaimy AL, Arthurs BJ, Lamoreaux WT, Demakas JJ, Mackay AR, Fairbanks RK, **Greeley DR**, Cooke BS, Lee CM.

12. Prospective Study Evaluating incobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the first 145 subjects with Cervical Dystonia. Tremor Other Hyperkinet Mov 2013;3: http://tremorjournal.org/article/view/139 Fernandez H, Pagan F, Danisi F, **Greeley D**, Jankovic J, Verma A, Sethi K, Pappert E.

_____ _____

Signature Date